322 results
Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or
Metformin Treatment ... /dc17-2231 #Metformin ... #CKD3 #CKD4 #Dosing
Diabetes Type 2 Medication Management and Titration Algorithm
- First line therapy is metformin and comprehensive lifestyle
line therapy is metformin ... Established ASCVD or CKD ... established ASCVD or CKD
Echocardiogram and POCUS Cardiology Windows and Anatomy
 • Parasternal Long Axis (PLAX)
 • Subcostal 4 Chamber
Echocardiogram and POCUS ... Subcostal 4 Chamber (S4C ... Apical 4 Chamber (A4C ... Apical 2 Chamber (A2C ... Echocardiogram #POCUS
Diabetes Combination Tablets - Estimated A1c Lowering 
Metformin + DPP4 
• Janumet (metformin + sitagliptin) 
•
Tablets - Estimated A1c ... Lowering Metformin ... DPP4 • Janumet (metformin ... • Jentadueto (metformin ... saxagliptin) Metformin
POCUS Echocardiography - Table of Cardiac Views and Windows
 • Parastemal Long-Axis View (PLAX)
 • Parasternal
POCUS Echocardiography ... -Chamber View (A4C ... -Chamber View (A5C ... -Chamber View (A2C ... Doppler #Anatomy #POCUS
Metformin in Diabetic Kidney Disease
Immediate release:
 • Initial 500 mg or 850 mg once daily
 •
Metformin in Diabetic ... eGFR < 30: Stop metformin ... do not initiate metformin ... annually if on metformin ... #CKD #pharmacology
Algorithm for Metformin Prescribing and Dosing in CKD
Dose Initiation - Immediate release:
 • Initial 500 mg
Algorithm for Metformin ... and Dosing in CKD ... maximum dose #Metformin ... Prescribing #Dosing #CKD
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Patients With CKD ... FDA recommends, metformin ... per 1.73 m2 with metformin ... #Diabetes #CKD # ... eGFR #Insulin #metformin
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
than SGLT2i and metformin ... in T2D and CKD. ... cardiovascular disease: CKD ... , #KDIGO2020 #CKD ... Management in CKD
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
modifications Metformin ... Improved outcomes in CKD